The company engages a third-party consultant on an as-needed basis to manage product development and manufacturing contractors. In November 2017, it entered into a Manufacturing Services Agreement with Patheon UK Limited, a wholly-owned subsidiary of Thermo Fisher, Inc., for the production of commercial quantities of Gimoti. This agreement obligates the company to purchase a specified percentage of Gimoti for commercial sale and remains effective until December 31, 2025, with automatic one-year renewals. Termination clauses address insolvency, regulatory actions, assignment to competitors, and material breaches.
In May 2016, the company established a Master Supply Agreement with Cosma S.p.A., designating Cosma as the exclusive commercial supplier of metoclopramide for Gimoti manufacture. Cosma supplies metoclopramide based on purchase orders without a minimum supply requirement. If Cosma discontinues supply or materially changes specifications, the company may require up to a two-year supply based on prior purchase orders. The supply agreement has a three-year term with automatic extensions linked to the commercial launch of Gimoti and successive one-year periods, with termination permitted upon written notice.
Evoke Pharma Inc's Comment on Supply Chain
The company engages a third-party consultant on an as-needed basis to manage product development and manufacturing contractors. In November 2017, it entered into a Manufacturing Services Agreement with Patheon UK Limited, a wholly-owned subsidiary of Thermo Fisher, Inc., for the production of commercial quantities of Gimoti. This agreement obligates the company to purchase a specified percentage of Gimoti for commercial sale and remains effective until December 31, 2025, with automatic one-year renewals. Termination clauses address insolvency, regulatory actions, assignment to competitors, and material breaches.
In May 2016, the company established a Master Supply Agreement with Cosma S.p.A., designating Cosma as the exclusive commercial supplier of metoclopramide for Gimoti manufacture. Cosma supplies metoclopramide based on purchase orders without a minimum supply requirement. If Cosma discontinues supply or materially changes specifications, the company may require up to a two-year supply based on prior purchase orders. The supply agreement has a three-year term with automatic extensions linked to the commercial launch of Gimoti and successive one-year periods, with termination permitted upon written notice.
Sources:
Evoke Pharma Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Evoke Pharma Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
